Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Milei Threatens Falkland Oil Firms With Sanctions 
Anthropic IPO Marketing Expected to Start in Mid-October 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Xiaomi Shares Jump on Europe EV Expansion Plan 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 27, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
